The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis

Objectives: To assess the effect and toxicity of CA125-targeted antibody used as maintenance therapy for advanced epithelial ovarian cancer (EOC). Materials and Methods: Two reviewers searched PubMed, Medline, Embase, VIP databases, and the references of selected articles for randomized controlled trials comparing maintenance CA125-targeted antibody treatment with placebo/observation. One-, two-, three-, and five-year overall survival (OS) and progression free survival (PFS) were collected. Incidence and severity of adverse events were extracted. Meta-analysis of combined risk ratio (RR) for OS , PFS, and toxicity were conducted. Results: Four trials including 1,259 women were identified. Meta-analysis showed the combined RR was 1.02 (95% CI, 0.85-1.22) for three-year OS and 0.98 (95% CI, 0.70-1.39) for the three-year PFS. This review found that abagovomab and oregovomab caused toxicity no more than placebo. Conclusions: CA125-targeted antibody used as maintenance therapy alone is not more effective than placebo but they were safe as maintenance therapy.

CA125-targeted antibody; Epithelial ovarian cancer; Maintenance therapy; Meta-analysis.

[1] Lesnock J.L., Farris C., Krivak T.C., Smith K.J., Markman M.: “Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer”. Gynecol. Oncol., 2011, 122, 473..

[2] Thigpen T.: “First-line therapy for ovarian carcinoma: what's next?” Can. Invest., 2004, 22, 21.

[3] Berek J.S., Taylor P.T., Gordon A., Cunningham M.J., Finkler N., Orr J. Jr., et al.: “Randomized, placebo-controlled study of Oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer”. J. Clin. Oncol., 2004, 22, 3507.

[4] Alberts D.S., Hannigan E.V., Liu P.Y., Jiang C., Wilczynski S., Copeland L., et al.: “Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidenceof disease after primary surgery and chemotherapy: An intergroup study”. Gynecol. Oncol., 2006, 100, 133.

[5] Bertelsen K., Jakobsen A., Stroyer J., Nielsen K., Sandberg E. Andersen J.E., et al.: “A prospective randomised comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA)”. Gynecol. Oncol., 1993, 49, 30.

[6] Lambert H.E., Rustin G.J., Gregory W.M., Nelstrop A.E.: “A randomised trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group Study”. Ann. Oncol., 1997, 8, 327.

[7] Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al.: “Phase 3 randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial”. J. Clin. Oncol., 2003, 21, 2460.

[8] Varia M.A., Stehman F.B., Bundy B.N., Benda J.A., Clarke-Pearson D.L., Alvarez R.D., et al.: “Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage 3 ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group”. J. Clin. Oncol., 2003, 21, 2849.

[9] Mannel R.S., Brady M.F., Kohn E.C., Hanjani P., Hiura M., Lee R., et al.: “A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 2011, 122, 89.

[10] Pecrelli S., Favalli G., Gadducci A., Katsaros D., Panici P.B., Carpi A., et. al.: “Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1”. J. Clin. Oncol., 2009, 27, 4642..

[11] Nicoletto M.O., Tumolo S., Falci C., Donach M., Visonà E., Rosabian A., et al.: “A randomized study of epithelial ovarian cancer: Is chemotherapy useful after complete remission?” Int. J. Med. Sci., 2004, 1, 116.

[12] Piccart M.J., Floquet A., Scarfone G., Willemse P.H., Emerich J., Vergote I., et al.: “Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase 3 study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy”. Int. J. Gynecol. Cancer, 2003, 13, 196.

[13] Pickel H., Lahousen M., Petru E., Stettner H., Hackl A., Kapp K., et al.: “Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer”. Gynecol. Oncol., 1999, 72, 215.

[14] Sorbe B.: “Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized controlled clinical trial comparing whole abdominal radiotherapy, chemotherapy and no further treatment”. Int. J. Gynecol. Cancer, 2003, 13, 278..

[15] Angele L.O., Fred C.S., Chris M.T., Boerman O.C., Massuger L.F., et al.: “The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review)”. Int. J. Oncol., 2008, 32, 1145.

[16] Ehlen T.G., Hoskins P.J., Miller D., Whiteside T.L., Nicodemus C.F., Schultes B.C., et al.: “A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer”. Int. J. Gynecol. Cancer, 2005, 15, 1023.

[17] Braly P., Nicodemus C.F., Chu C., Collins Y., Edwards R., Gordon A., et al.: “The Immune adjuvant properties of front-line carboplatinpaclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer”. J. Immunother., 2009, 32, 54.

[18] Gordon A.N., Schultes B.C., Gallion H., Edwards R., Whiteside T.L., Cermak J.M., et al.: “CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients”. Gynecol. Oncol., 2004, 94, 340.

[19] Wagner U., Schlebusch H., Köhler S., Schmolling J., Grünn U., Krebs D.: “Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125”. Hybridoma, 1997, 16, 33.

[20] Reinartz S., Köhler S., Schlebusch H., Krista K., Giffels P., Renke K., et al.: “Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunologicalresponse and survival (phase Ib/II)”. Clin. Cancer Res., 2004, 10, 1580.

[21] Pfisterer J., Bois A., Sehouli J., Loibl S., Reinartz S., Reuss A., et al.: “The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR”. Ann. Oncol., 2006, 17, 1568.

[22] Higgins J.P.T., Green S. (eds).: “Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]”. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook. org.

[23] Wagner U., Köhler S., Reinartz S., Giffels P., Huober J., Renke K., et al.: “Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K.A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001”. Clin. Cancer Res., 2001, 7, 1154.

[24] Berek J.S., Taylor P.T., Nicodemus C.F.: “CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer”. J. Immunother., 2008, 31, 207.

[25] Berek J., Taylor P., McGuire W., Smith M., Schultes B., Nicodemus C.F., et al.: “Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer”. J. Clin. Oncol., 2009, 27, 418.

[26] Sabbatini P., Harter P., Scambia G., Sehouli J., Meier W., Wimberger P., et al.: “Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study”. J. Clin. Oncol., 2013, 31, 1554..

[27] Vergote I., Rustin G.J., Eisenhauer E.A., Kristensen G.B., Pujade- Lauraine E., Parmar M.K., et al.: “Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup”. J. Natl. Cancer Inst., 2000, 92, 1534.